vs
Side-by-side financial comparison of Massimo Group (MAMO) and Sight Sciences, Inc. (SGHT). Click either name above to swap in a different company.
Massimo Group is the larger business by last-quarter revenue ($21.0M vs $20.4M, roughly 1.0× Sight Sciences, Inc.). Massimo Group runs the higher net margin — 9.5% vs -20.4%, a 29.9% gap on every dollar of revenue. On growth, Massimo Group posted the faster year-over-year revenue change (15.7% vs 6.9%). Over the past eight quarters, Sight Sciences, Inc.'s revenue compounded faster (2.9% CAGR vs -16.5%).
Massimo Dutti, S.A. is a Spanish premium clothing retailer specializing in cashmere and wool products, established in 1985 and owned by Spanish multinational company Inditex, the parent company of Zara, Pull&Bear, and other brands.
Sight Sciences, Inc. is a commercial-stage medical technology company focused on developing and commercializing innovative products for treating common eye conditions including glaucoma and dry eye disease. It offers minimally invasive surgical devices and non-surgical care solutions, primarily serving ophthalmology clinicians and patients across the United States.
MAMO vs SGHT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $21.0M | $20.4M |
| Net Profit | $2.0M | $-4.2M |
| Gross Margin | 41.5% | 87.3% |
| Operating Margin | 13.1% | -18.0% |
| Net Margin | 9.5% | -20.4% |
| Revenue YoY | 15.7% | 6.9% |
| Net Profit YoY | 215.0% | 64.9% |
| EPS (diluted) | $0.05 | $-0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $21.0M | $20.4M | ||
| Q3 25 | $17.0M | $19.9M | ||
| Q2 25 | $18.9M | $19.6M | ||
| Q1 25 | $14.9M | $17.5M | ||
| Q4 24 | $18.2M | $19.1M | ||
| Q3 24 | $25.6M | $20.2M | ||
| Q2 24 | $35.4M | $21.4M | ||
| Q1 24 | $30.2M | $19.3M |
| Q4 25 | $2.0M | $-4.2M | ||
| Q3 25 | $1.5M | $-8.2M | ||
| Q2 25 | $77.7K | $-11.9M | ||
| Q1 25 | $-2.1M | $-14.2M | ||
| Q4 24 | $-1.7M | $-11.8M | ||
| Q3 24 | $-2.5M | $-11.1M | ||
| Q2 24 | $2.8M | $-12.3M | ||
| Q1 24 | $3.2M | $-16.3M |
| Q4 25 | 41.5% | 87.3% | ||
| Q3 25 | 42.0% | 86.4% | ||
| Q2 25 | 36.3% | 84.8% | ||
| Q1 25 | 28.4% | 86.2% | ||
| Q4 24 | 19.6% | 86.8% | ||
| Q3 24 | 27.2% | 83.9% | ||
| Q2 24 | 32.5% | 85.8% | ||
| Q1 24 | 34.7% | 85.5% |
| Q4 25 | 13.1% | -18.0% | ||
| Q3 25 | 10.5% | -39.7% | ||
| Q2 25 | 0.8% | -59.6% | ||
| Q1 25 | -18.2% | -79.2% | ||
| Q4 24 | -15.4% | -62.5% | ||
| Q3 24 | 1.2% | -55.7% | ||
| Q2 24 | 10.1% | -59.2% | ||
| Q1 24 | 13.2% | -76.4% |
| Q4 25 | 9.5% | -20.4% | ||
| Q3 25 | 9.0% | -41.0% | ||
| Q2 25 | 0.4% | -61.0% | ||
| Q1 25 | -14.0% | -80.8% | ||
| Q4 24 | -9.5% | -62.1% | ||
| Q3 24 | -9.8% | -54.9% | ||
| Q2 24 | 8.0% | -57.7% | ||
| Q1 24 | 10.6% | -84.4% |
| Q4 25 | $0.05 | $-0.07 | ||
| Q3 25 | $0.04 | $-0.16 | ||
| Q2 25 | $0.00 | $-0.23 | ||
| Q1 25 | $-0.05 | $-0.28 | ||
| Q4 24 | $-0.05 | $-0.23 | ||
| Q3 24 | $-0.06 | $-0.22 | ||
| Q2 24 | $0.07 | $-0.25 | ||
| Q1 24 | $0.08 | $-0.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $5.8M | $92.0M |
| Total DebtLower is stronger | — | $42.4M |
| Stockholders' EquityBook value | $23.7M | $63.9M |
| Total Assets | $51.4M | $115.3M |
| Debt / EquityLower = less leverage | — | 0.66× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.8M | $92.0M | ||
| Q3 25 | $2.6M | $92.4M | ||
| Q2 25 | — | $101.5M | ||
| Q1 25 | $3.0M | $108.8M | ||
| Q4 24 | $10.2M | $120.4M | ||
| Q3 24 | — | $118.6M | ||
| Q2 24 | — | $118.2M | ||
| Q1 24 | — | $127.3M |
| Q4 25 | — | $42.4M | ||
| Q3 25 | — | $42.4M | ||
| Q2 25 | — | $42.4M | ||
| Q1 25 | — | $42.4M | ||
| Q4 24 | — | $40.0M | ||
| Q3 24 | — | $37.1M | ||
| Q2 24 | — | $35.0M | ||
| Q1 24 | — | $35.0M |
| Q4 25 | $23.7M | $63.9M | ||
| Q3 25 | $21.7M | $64.3M | ||
| Q2 25 | $20.2M | $70.0M | ||
| Q1 25 | $19.9M | $77.6M | ||
| Q4 24 | $21.7M | $87.5M | ||
| Q3 24 | $22.5M | $95.0M | ||
| Q2 24 | $24.7M | $101.6M | ||
| Q1 24 | $18.1M | $109.2M |
| Q4 25 | $51.4M | $115.3M | ||
| Q3 25 | $44.4M | $116.3M | ||
| Q2 25 | $45.9M | $122.0M | ||
| Q1 25 | $46.4M | $129.7M | ||
| Q4 24 | $54.9M | $142.8M | ||
| Q3 24 | $57.1M | $143.6M | ||
| Q2 24 | $49.9M | $149.7M | ||
| Q1 24 | $47.3M | $155.6M |
| Q4 25 | — | 0.66× | ||
| Q3 25 | — | 0.66× | ||
| Q2 25 | — | 0.61× | ||
| Q1 25 | — | 0.55× | ||
| Q4 24 | — | 0.46× | ||
| Q3 24 | — | 0.39× | ||
| Q2 24 | — | 0.34× | ||
| Q1 24 | — | 0.32× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $4.0M | $-1.8M |
| Free Cash FlowOCF − Capex | — | $-2.0M |
| FCF MarginFCF / Revenue | — | -9.7% |
| Capex IntensityCapex / Revenue | — | 0.8% |
| Cash ConversionOCF / Net Profit | 2.01× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $4.0M | $-1.8M | ||
| Q3 25 | $633.2K | $-8.7M | ||
| Q2 25 | $-1.4M | $-7.5M | ||
| Q1 25 | $-3.3M | $-11.6M | ||
| Q4 24 | $9.1M | $-3.5M | ||
| Q3 24 | $4.7M | $362.0K | ||
| Q2 24 | $-6.5M | $-9.5M | ||
| Q1 24 | $-637.0K | $-9.8M |
| Q4 25 | — | $-2.0M | ||
| Q3 25 | — | $-8.9M | ||
| Q2 25 | — | $-7.8M | ||
| Q1 25 | — | — | ||
| Q4 24 | $9.0M | $-3.6M | ||
| Q3 24 | $4.6M | $311.0K | ||
| Q2 24 | $-6.7M | $-9.5M | ||
| Q1 24 | $-741.4K | $-9.9M |
| Q4 25 | — | -9.7% | ||
| Q3 25 | — | -44.7% | ||
| Q2 25 | — | -39.6% | ||
| Q1 25 | — | — | ||
| Q4 24 | 49.7% | -18.9% | ||
| Q3 24 | 18.1% | 1.5% | ||
| Q2 24 | -19.0% | -44.7% | ||
| Q1 24 | -2.5% | -51.4% |
| Q4 25 | — | 0.8% | ||
| Q3 25 | — | 0.9% | ||
| Q2 25 | — | 1.1% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | 0.2% | 0.7% | ||
| Q3 24 | 0.3% | 0.3% | ||
| Q2 24 | 0.7% | 0.4% | ||
| Q1 24 | 0.3% | 0.6% |
| Q4 25 | 2.01× | — | ||
| Q3 25 | 0.41× | — | ||
| Q2 25 | -17.92× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -2.30× | — | ||
| Q1 24 | -0.20× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MAMO
Segment breakdown not available.
SGHT
| Surgical Glaucoma | $19.7M | 96% |
| Other | $724.0K | 4% |
